Sign In
Buy SAGE
$8.68
+0 (+0%)
At Close: Oct 30, 2025
NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sage Therapeutics, Inc. (NASDAQ: SAGE) between April 12, 2021 an
Investors in Sage Therapeutics, Inc. Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights – SAGE
06:15pm, Tuesday, 22'nd Oct 2024
NEW YORK, NY / ACCESSWIRE / October 22, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage Therapeutics
05:52pm, Tuesday, 22'nd Oct 2024
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Sage To Contact Him Directly To Discuss Their Options NEW YORK CITY
Investors in Sage Therapeutics, Inc. Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - SAGE
04:30pm, Tuesday, 22'nd Oct 2024
NEW YORK, NY / ACCESSWIRE / October 22, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities
SAGE LAWSUIT ALERT: Levi & Korsinsky Notifies Sage Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
04:00pm, Tuesday, 22'nd Oct 2024
NEW YORK, NY / ACCESSWIRE / October 22, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities
NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed ag
NEW YORK, NY / ACCESSWIRE / October 22, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities
Sage Therapeutics, Inc. (SAGE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
11:05am, Tuesday, 22'nd Oct 2024
Sage Therapeutics (SAGE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAGE LAWSUIT ALERT: Levi & Korsinsky Notifies Sage Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
09:30pm, Monday, 21'st Oct 2024
NEW YORK, NY / ACCESSWIRE / October 21, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities
NEW YORK, NY / ACCESSWIRE / October 21, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities
Investors can contact the law firm at no cost to learn more about recovering their losses
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit
04:17pm, Monday, 21'st Oct 2024
NEW YORK , Oct. 21, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sage Therapeutics, Inc. (NASDAQ: SAGE) between April 12, 2021 and July 2
NEW YORK, NY / ACCESSWIRE / October 21, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Sage Therapeutics Lawsuit - SAGE
11:30am, Monday, 21'st Oct 2024
NEW YORK, NY / ACCESSWIRE / October 21, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities
LOS ANGELES, CA / ACCESSWIRE / October 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sage Therapeutics, Inc. ("Sage
